Glomerulonefritis por cambios mínimos post vacuna COVID-19 AstraZeneca
Palabras clave:
COVID-19, coronavirus, síndrome respiratorio agudo severo, SARS-CoV-2, vacunación, síndrome nefrótico de cambios mínimos
Resumen
Reportamos un caso de una mujer de 28 años, con síndrome nefrótico debido a glomerulonefritis por cambios mínimos 48 horas después de la administración de la vacuna contra SARS-CoV2 de AstraZeneca. La paciente tuvo síndrome nefrótico idiopático en la infancia tratado empíricamente con corticoides y ciclosporina, en remisión completa desde los 9 años. Algunos reportes sugieren que determinadas enfermedades glomerulares podrían asociarse infrecuentemente a las vacunas.
Citas
1) Clajus C, Spiegel J, Bröcker V, Chatzikyrkou C, Kielstein JT. Minimal change nephrotic syndrome in an 82 year old patient following a tetanus-diphteria-poliomyelitis-vaccination. BMC Nephrol. 2009;10:21. doi: 10.1186/1471-2369-10-21.
2) Kielstein JT, Termühlen L, Sohn J, Kliem V. Minimal change nephrotic syndrome in a 65-year-old patient following influenza vaccination. Clin Nephrol. 2000;54(3):246-8.
3) Kikuchi Y, Imakiire T, Hyodo T, Higashi K, Henmi N, Suzuki S, et al. Minimal change nephrotic syndrome, lymphadenopathy and hyperimmunoglobulinemia after immunization with a pneumococcal vaccine. Clin Nephrol. 2002;58(1):68-72. doi: 10.5414/cnp58068.
4) Abeyagunawardena AS, Goldblatt D, Andrews N, Trompeter RS. Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome. Lancet. 2003;362(9382):449-50. doi: 10.1016/s0140-6736(03)14072-x.
5) Lebedev L, Sapojnikov M, Wechsler A, Varadi-Levi R, Zamir D, Tobar A, et al. Minimal change disease following the Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis. 2021;78(1):142-5. doi: 10.1053/j.ajkd.2021.03.010.
6) D'Agati VD, Kudose S, Bomback AS, Adamidis A, Tartini A. Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine. Kidney Int. 2021;100(2):461-3. doi: 10.1016/j.kint.2021.04.035.
7) Morlidge C, El-Kateb S, Jeevaratnam P, Thompson B. Relapse of minimal change disease following the AstraZeneca COVID-19 vaccine. Kidney Int. 2021;100(2):459. doi: 10.1016/j.kint.2021.06.005.
8) Leclerc S, Royal V, Lamarche C, Laurin LP. Minimal change disease with severe acute kidney injury following the Oxford-AstraZeneca COVID-19 vaccine: a case report. Am J Kidney Dis. 2021;78(4):607-10. doi: 10.1053/j.ajkd.2021.06.008.
9) Cara-Fuentes GM, Johnson RJ, Garin EH. Cytokines as active factors in minimal change nephrotic syndrome. En: Kaneko K., ed. Molecular mechanisms in the pathogenesis of idiopathic nephrotic syndrome. Springer, Tokyo: 2016, p. 105-40. https://doi.org/10.1007/978-4-431-55270-3_8.
10) Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974;2(7880):556-60. doi: 10.1016/s0140-6736(74)91880-7.
11) Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal change disease. Clin J Am Soc Nephrol. 2017;12(2):332-45. doi: 10.2215/CJN.05000516.
12) Gillion V, Jadoul M, Demoulin N, Aydin S, Devresse A. Granulomatous vasculitis after the AstraZeneca anti-SARS-CoV-2 vaccine. Kidney Int. 2021;100(3):706-7. doi: 10.1016/j.kint.2021.06.033.
13) Anderegg MA, Liu M, Saganas C, Montani M, Vogt B, Huynh-Do U, et al. De novo vasculitis after mRNA-1273 (Moderna) vaccination. Kidney Int. 2021;100(2):474-6. doi: 10.1016/j.kint.2021.05.016.
14) Sacker A, Kung V, Andeen N. Anti-GBM nephritis with mesangial IgA deposits after SARS-CoV-2 mRNA vaccination. Kidney Int. 2021;100(2):471-2. doi: 10.1016/j.kint.2021.06.006.
15) Rahim SEG, Lin JT, Wang JC. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. Kidney Int. 2021;100(1):238. doi: 10.1016/j.kint.2021.04.024.
16) Aydın MF, Yıldız A, Oruç A, Sezen M, Dilek K, Güllülü M, et al. Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination. Kidney Int. 2021;100(2):464-5. doi: 10.1016/j.kint.2021.05.001.
17) Ciuntu A. The role of cell signaling molecules in the pathogenesis of glomerulonephritis in children. Moldovan Med J. 2021;64(2):37-4. doi: 10.52418/moldovan-med-j.64-2.21.07.
18) Kudose S, Batal I, Santoriello D, Xu K, Barasch J, Peleg Y, et al. Kidney biopsy findings in patients with COVID-19. J Am Soc Nephrol. 2020;31(9):1959-68. doi: 10.1681/ASN.2020060802.
19) Ishimoto T, Shimada M, Gabriela G, Kosugi T, Sato W, Lee PY, et al. Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice. Nephrol Dial Transplant. 2013;28(6):1439-46. doi: 10.1093/ndt/gfs543.
20) Xing CY, Saleem MA, Coward RJ, Ni L, Witherden IR, Mathieson PW. Direct effects of dexamethasone on human podocytes. Kidney Int. 2006;70(6):1038-45. doi: 10.1038/sj.ki.5001655.
2) Kielstein JT, Termühlen L, Sohn J, Kliem V. Minimal change nephrotic syndrome in a 65-year-old patient following influenza vaccination. Clin Nephrol. 2000;54(3):246-8.
3) Kikuchi Y, Imakiire T, Hyodo T, Higashi K, Henmi N, Suzuki S, et al. Minimal change nephrotic syndrome, lymphadenopathy and hyperimmunoglobulinemia after immunization with a pneumococcal vaccine. Clin Nephrol. 2002;58(1):68-72. doi: 10.5414/cnp58068.
4) Abeyagunawardena AS, Goldblatt D, Andrews N, Trompeter RS. Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome. Lancet. 2003;362(9382):449-50. doi: 10.1016/s0140-6736(03)14072-x.
5) Lebedev L, Sapojnikov M, Wechsler A, Varadi-Levi R, Zamir D, Tobar A, et al. Minimal change disease following the Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis. 2021;78(1):142-5. doi: 10.1053/j.ajkd.2021.03.010.
6) D'Agati VD, Kudose S, Bomback AS, Adamidis A, Tartini A. Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine. Kidney Int. 2021;100(2):461-3. doi: 10.1016/j.kint.2021.04.035.
7) Morlidge C, El-Kateb S, Jeevaratnam P, Thompson B. Relapse of minimal change disease following the AstraZeneca COVID-19 vaccine. Kidney Int. 2021;100(2):459. doi: 10.1016/j.kint.2021.06.005.
8) Leclerc S, Royal V, Lamarche C, Laurin LP. Minimal change disease with severe acute kidney injury following the Oxford-AstraZeneca COVID-19 vaccine: a case report. Am J Kidney Dis. 2021;78(4):607-10. doi: 10.1053/j.ajkd.2021.06.008.
9) Cara-Fuentes GM, Johnson RJ, Garin EH. Cytokines as active factors in minimal change nephrotic syndrome. En: Kaneko K., ed. Molecular mechanisms in the pathogenesis of idiopathic nephrotic syndrome. Springer, Tokyo: 2016, p. 105-40. https://doi.org/10.1007/978-4-431-55270-3_8.
10) Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974;2(7880):556-60. doi: 10.1016/s0140-6736(74)91880-7.
11) Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal change disease. Clin J Am Soc Nephrol. 2017;12(2):332-45. doi: 10.2215/CJN.05000516.
12) Gillion V, Jadoul M, Demoulin N, Aydin S, Devresse A. Granulomatous vasculitis after the AstraZeneca anti-SARS-CoV-2 vaccine. Kidney Int. 2021;100(3):706-7. doi: 10.1016/j.kint.2021.06.033.
13) Anderegg MA, Liu M, Saganas C, Montani M, Vogt B, Huynh-Do U, et al. De novo vasculitis after mRNA-1273 (Moderna) vaccination. Kidney Int. 2021;100(2):474-6. doi: 10.1016/j.kint.2021.05.016.
14) Sacker A, Kung V, Andeen N. Anti-GBM nephritis with mesangial IgA deposits after SARS-CoV-2 mRNA vaccination. Kidney Int. 2021;100(2):471-2. doi: 10.1016/j.kint.2021.06.006.
15) Rahim SEG, Lin JT, Wang JC. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. Kidney Int. 2021;100(1):238. doi: 10.1016/j.kint.2021.04.024.
16) Aydın MF, Yıldız A, Oruç A, Sezen M, Dilek K, Güllülü M, et al. Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination. Kidney Int. 2021;100(2):464-5. doi: 10.1016/j.kint.2021.05.001.
17) Ciuntu A. The role of cell signaling molecules in the pathogenesis of glomerulonephritis in children. Moldovan Med J. 2021;64(2):37-4. doi: 10.52418/moldovan-med-j.64-2.21.07.
18) Kudose S, Batal I, Santoriello D, Xu K, Barasch J, Peleg Y, et al. Kidney biopsy findings in patients with COVID-19. J Am Soc Nephrol. 2020;31(9):1959-68. doi: 10.1681/ASN.2020060802.
19) Ishimoto T, Shimada M, Gabriela G, Kosugi T, Sato W, Lee PY, et al. Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice. Nephrol Dial Transplant. 2013;28(6):1439-46. doi: 10.1093/ndt/gfs543.
20) Xing CY, Saleem MA, Coward RJ, Ni L, Witherden IR, Mathieson PW. Direct effects of dexamethasone on human podocytes. Kidney Int. 2006;70(6):1038-45. doi: 10.1038/sj.ki.5001655.
Publicado
2022-03-16
Cómo citar
1.
Arias C, Pérez De Pedro F, Caliva E, Farías B, Iotti A, Rubio D. Glomerulonefritis por cambios mínimos post vacuna COVID-19 AstraZeneca. Rev Nefrol Dial Traspl. [Internet]. 16 de marzo de 2022 [citado 25 de diciembre de 2024];42(1):65-8. Disponible en: http://revistarenal.org.ar/index.php/rndt/article/view/758
Sección
Casuística
Derechos de autor 2022 Revista de Nefrología, Diálisis y Trasplante
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0.
